<DOC>
	<DOCNO>NCT02391545</DOCNO>
	<brief_summary>A Two-arm , Phase 1b/2 Study IPI-145 Administered Combination Rituximab Obinutuzumab Subjects Previously Untreated CD20+ Follicular Lymphoma .</brief_summary>
	<brief_title>A Study Duvelisib Combination With Rituximab Obinutuzumab Subjects With Previously Untreated CD20+ Follicular Lymphoma ( CONTEMPO )</brief_title>
	<detailed_description>This two-arm , open-label , Phase 1b/2 trial design evaluate safety efficacy IPI-145 combination rituximab IPI-145 combination obinutuzumab subject previously untreated CD20+ FL . The study conduct two part , Safety Lead-in ( Part 1 ) follow randomize , 2-Stage Design Part 2 . Each treatment arm assess independently dose limit toxicity ( DLT ) within Part 1 .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Diagnosis CD20+ , follicular lymphoma treat CD20immunophenotyping tumor document Bcell follicular lymphoma Stage II disease bulky disease ( â‰¥ 7cm lesion ) , Stage III , Stage IV disease Disease require treatment base Investigator 's opinion ( e.g. , meet GELF criterion ) At least one measurable lesion &gt; 1.5 cm least one dimension Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; =2 ( correspond Karnofsky Performance Status [ KPS ] &gt; =60 % ) Received systemic treatment lymphoma chemotherapy , immunotherapy , radiotherapy , investigational agent , radioimmunotherapy . Clinical evidence transformation aggressive subtype lymphoma grade 3B follicular lymphoma Severe allergic anaphylactic reaction monoclonal antibody therapy , murine protein , know hypersensitivity study drug Prior allogeneic hematopoietic stem cell transplant Prior , current chronic hepatitis B hepatitis C infection Human immunodeficiency virus ( HIV ) infection Human T Cell Lymphotropic Virus 1 ( HTLV1 ) infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Follicular Lymphoma</keyword>
	<keyword>Previously Untreated</keyword>
</DOC>